Ionis Pharmaceuticals IONS Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpense.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's interest expense?
- Ionis Pharmaceuticals (IONS) reported interest expense of $5.16M in Q1 2026.
- How has Ionis Pharmaceuticals's interest expense changed year-over-year?
- Ionis Pharmaceuticals's interest expense increased by 25.6% year-over-year, from $4.11M to $5.16M.
- What is the long-term trend for Ionis Pharmaceuticals's interest expense?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's interest expense has grown at a 16.8% compound annual growth rate (CAGR), from $12.66M to $17.26M.
- What does interest expense mean?
- The cost of interest paid on debt and other financial liabilities.
- How do you interpret interest expense?
- A decrease indicates lower debt levels or more favorable interest rates, reducing the financial burden on the company.
- How does interest expense compare across companies?
- Standard interest expense metric used to assess debt service costs.